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Influence of the Escherichia coli Capsule on
Complement Fixation and on Phagocytosis and
Killing by Human Phagocytes
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A B S T R A C T To define mechanisms by which poly-
saccharide capsules confer enhanced virulence on
gram-negative bacteria, we examined the effect of the
Escherichia coli capsule on complement fixation to the
bacterial surface and on phagocytosis and killing of
these bacteria by mouse macrophages and human poly-
morphonuclear leukocytes (PMN) andl mnonocytes.
When E. coli were attached to mouse macrophages
with concanavalin A, the macrophages readily phago-
cytosed unencapsulated but not encapsulated bacteria
even in the presence of fresh mouse serum; macro-
phages did not phagocytose encapsulated E. coli unless
antibacterial or anti-Con A antibody was added.
Similarly, when these bacteria were attached to human
PMN with Con A, PMN ingested unencapsulated but
not encapsulated E. coli.
PMN phagocytosed and killed encapsulated serum-
resistant E. coli only in the presence of both comple-
ment and antibacterial antibody; PMN phagocytosed
and killed unencapsulated E. coli of the same strain in
the presence of complement alone. Fluorescence
microscopy showed that antibody had to be present for
encapsulated but not unencapsulated E. coli to fix com-
plement to its surface.
To examine the role of the complement receptors of
human PMN and monocytes in phagocytosis and killing
ofencapsulated E. coli, we used human and rabbit anti-
bacterial immunoglobulin (Ig)M to fix complement to
the bacteria. PMN and monocytes phagocytosed and
killed encapsulated E. coli in the presence of both
IgM and complement, but not in the presence of either
serum opsonin alone. In the presence of antibacterial
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IgG, PMN and monocytes required complement to
effectively phagocytose and kill the E. coli.
We conclude that (a) attachment by itself results in
ingestion of unencapsulated but not encapsulated E.
coli; (b) under physiologic conditions, E. coli are not
phagocytosed or killed effectively by PMN or mono-
cytes unless complement is fixed to their surface; (c)
in the absence of antibody, the E. coli capsule blocks
complement fixation to the bacterial surface probably
by masking surface components, such as lipopolysac-
charide, capable of activating the complement path-
way; (d) the E. coli capsule imposes a requirement
for specific antibacterial antibody for complement
fixation; and (e) the complement receptor of human
PMN and monocytes mediates phagocytosis of com-
plement-coated encapsulated bacteria and is the pri-
mary mediator of phagocytosis and killing of these
bacteria.
INTRODUCTION
For many bacterial species, the presence of a capsule
has been identified as a critical determinant of viru-
lence. For some, such as Escherichia coli, the degree
of virulence is a function of both the size and composi-
tion of the capsule (1). In experimental animals, en-
capsulated forms are more virulent than unencapsulated
forms (2, 3), and the degree of virulence is propor-
tional to the quantity of capsular (K) antigen expressed
on the bacterial surface (4).
Most E. coli isolated from human infections are en-
capsulated (1, 5). E. coli isolated from the urine of pa-
tients with pyelonephritis contain especially large
amounts of capsular antigen (6-8), and certain capsular
serotypes, most notably Kl, predominate in these pa-
tients and in infants with E. coli meningitis (6, 9-11).
In view of the importance of encapsulated E. coli
and other encapsulated gram-negative bacteria as hu-
man pathogens, it is surprising that so little is knowni of
the role(s) of the capsule in enhancing virulence.
Several investigators have reported that a capsule re-
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duces the bactericidal effects of serum on E. coli and
enhances the ability of this organism to resist phago-
cytosis (2, 4, 12, 13). Others have shown that anticap-
sular antibody has a protective effect on rabbits and
mice inoculated with encapsulated E. coli (14, 15).
These findings suggested to us that the capsule may
alter the binding of complement to the E. coli surface.
Complement activation by E. coli and other gram-
negative bacteria has been examined almost exclu-
sively in unencapsulated strains. Thus, although it is
known that unencapsulated E. coli fix complement via
the alternative complement pathway (16-18), virtually
nothing is known about complement fixation or con-
sumption by encapsulated E. coli. Similarly, studies of
phagocytosis ofE. coli have focused on unencapsulated
E. coli, particularly the laboratory-adapted and rough
E. coli K12 strain, or on encapsulated E. coli that have
been heat-killed and thereby have had their capsule
destroyed. Such studies may not be relevant to the
in vivo situation where pathogenic bacteria are en-
capsulated.
We undertook this study to define the mechanisms
by which capsules promote virulence of gram-negative
bacteria. In our studies, we used an encapsulated E. coli
strain (serotype 09:K29:H-) originally isolated from
human peritoneum (19), and unencapsulated mutant
strains bearing the 09 somatic antigens. We chose these
strains because the chemical structures of the 09
siomatic (20) and K29 capsulatr (21) antigens have been
determined and both are composed of repeating poly-
saccharide subunits containing the specific carbohy-
drate-combining site (22) for the plant lectin concana-
valin A (Con A).' The presence of Con A binding sites
on the bacteria allowed us to attach the bacteria to the
surface of mouse and human leukocytes with this lectin
and study bacteria-phagocyte interactions in the ab-
sence of the two major serum opsonins, antibody and
complement. We shall demonstrate that the presence
of a capsule markedly alters the interactions of E. coli
with serum complement and with the surface of phago-
cytic leukocytes. Additionally, we shall characterize
the roles of antibody and complement in phagocytosis
and killing of encapsulated E. coli by phagocytic leu-
kocytes.
METHODS
Reagents. Con A, three times crystallized and lyophilized
(Miles-Yeda Ltd., Kankakee, Ill.); a-methyl-D-mannopyrano-
IAbbreviations used in this paper: Abs S, human serum
absorbed with E. coli K+ and K-; AD, agglutinating dose;
CFU, colony-forming units; Con A, concanavalin A; E. coli
K+, E. coli, serotype 09:K29:H-; E. coli K-, E. coli, serotype
09:K29-:H-; HBSS, Hanks' balanced salt solution; HI, heat-
inactivated; NS, normal human serum; PBS, phosphate-
buffered saline with Ca++ and Mg++ ions; PD, PBS without
Ca++ and Mg++; PMN, human polymorphonuclear leukocytes;
RBC, erythrocytes; TSB, tryptic soy broth.
side (a-MM), grade III (Sigma Chemical Co., St. Louis, Mo.);
glutaraldehyde 50% (Electron Microscopy Sciences, Fort
Washington, Pa.).
Antisera and standards. Goat anti-Con A (Miles-Yeda
Ltd.); goat anti-human IgG, anti-human IgM, anti-rabbit IgG,
anti-rabbit IgM, all heavy chain specific; goat anti-human
complement C3, IgG fraction, rhodamine conjugated; and
human fraction rich in IgG (no IgA, no IgM) or IgM (no
IgA, no IgG) (N. L. Cappel Laboratories Inc., Cochranville,
Pa.).
Media. Dulbecco's phosphate-buffered saline with Ca++
and Mg"+ ions (PBS) (23); Hanks' balanced salt solution
(HBSS) 10 x (Grand Island Biological Co., Grand Island, N. Y.),
adjusted to pH 7.4; PBS without Ca++ and Mg++ (PD);
tryptic soy broth (TSB) (Difco Laboratories, Detroit, Mich.);
minimal essential medium without glucose (24).
Polymorphonuclear leukocytes (PMN). Blood from a
single healthy donor (type AB+) was collected in a heparin-
ized syringe, mixed 1:1 with dextran 6% wt/vol in 0.9% saline
(Dextran 75, Abbott Laboratories, Chicago, Ill.), and sedi-
mented at 24°C. PMN were separated from the leukocyte-
rich supernate by centrifugation over a discontinuous gradient
of Ficoll (Ficoll 400, Pharmacia Fine Chemicals, Piscataway,
N. J.) and sodium diatrizoate (Hypaque sodium 50%, Win-
throp Laboratories, New York) as described (25). The granulo-
cyte-rich fraction thus obtained was washed twice in PBS (40C)
by centrifugation at 200 g for 10 min at 4°C after which resid-
ual erythrocytes were lysed by a 1-min exposure to 0.2%
saline. Isotonicity was rapidly restored with 1.6% saline, and
the cells (>99% PMN) were pelleted, resuspended in HBSS,
counted in an improved Neubauer Chamber (Clay Adams,
Div. Becton, Dickinson & Co., Parsippany, N. J.), stored at
0°C at the required concentration and used within 30 min of
purification. Viability was >99% by the criterion of trypan
blue exclusion.
Human monocytes. Heparinized blood was diluted 1:1
in 0.9% saline and the mononuclear fraction obtained by cen-
trifugation at 800 g for 30 min at 240C over a Ficoll-sodium
diatrizoate solution (Ficoll-Paque, Pharmacia Fine Chemicals)
as described (26). The mononuclear cells were collected,
washed, purified of erythrocytes, and resuspended in HBSS
exactly as described for PMN. A sample of the suspension
was cytocentrifuged (Cytospin, Shandron Southern Instru-
ments Inc., Sewickley, Pa.) and stained. A differential cell
count was done in each experiment, and the monocyte con-
centration was adjusted to the required concentration; the cell
population (>99% viable by trypan blue exclusion) contained
-1.5% PMN, 40% monocytes, and 58.5% lymphocytes.
Mouse peritoneal inacrophages. Resident and thioglycol-
late-elicited mouse peritoneal macrophages were harvested
and cultured on 13-mm Diam glass coverslips as described (27).
Bacteria. E. coli, serotype 09:K29:H- (E. coli K+), strain
Bi 161-42, was kindly provided by Dr. Frits and Dr. Ida
0rskov, International Escherichia Centre, Statens Serumin-
stitut, Copenhagen, Denmark. E. coli, serotype 09:K29-:H-
(E. coli K-), a spontaneously occurring unencapsulated mutant
of strain Bi 161-42, was isolated from a colony of the parent
strain on the basis of colonial morphology. The mutant was
shown to have a biochemical and antibiotic sensitivity (anti-
biogram) profile identical to the parent strain; these tests
were generously performed by the Laboratory ofMicrobiology,
The New York Hospital-Cornell Medical Center, New York.
E. coli, serotype 09:K9-:H12 (E. coli 09:K9-:H12), strain
x43, an unencapsulated mutant ofE. coli, serotype 09:K9:H 12,
strain Bi 316/42, was also provided by Dr. Orskov.
E. coli K+, K-, and 09:K9-:H12, adjusted to 1% vol/vol
suspensions in PBS (OD standardized, see below), were
agglutinated by 2333, -4, and -16 ,ug/ml of Con A. E. coli
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K+ was strongly agglutinated (and exhibited a quellung re-
action) with rabbit anti-09:K29 antiserum (prepared against
the strain); it was not agglutinated by rabbit anti-09 anti
serum (prepared against boiled E. coli, serotype 09:K9:H12,
strain Bi 316/42). The E. coli K- ancd 09:K9-:H12 strains
were agglutinated by both the anti-09:K29 and the anti-09
antisera. Both antisera were kindly provided by Dr. Orskov.
E. coli K+ exhibited a large capsule when examined by Preisz'
wetfield India Ink method (28).
For stock cultures, a highly mucoid E. coli K+, an E. coli
K-, or an E. coli 09:K9-:H12 colony was grown in TSB at
37°C on a rotatory shaker to mid-log phase (OD of 0.300 at
540 nm measured in a Coleman 44 model spectrophotometer
[Perkin-Elmer Corp., Norwalk, Conn.]) and the culture stored
at -70°C in 10% glycerol. As needed, cultures were thawed
and cultured on TSB agar. An appropriate colony was picked,
grown up on TSB agar, and held at room temperature for 2-7 d.
14-18 h before an experiment, an appropriate colony was
again picked and grown up on TSB agar at 37°C; a standard
inoculum from this growth was suspended in 150 ml of TSB
and grown at 37°C to an OD of 0.300 at 540 nm. The bac-
teria were then collected by cenitrifugation at 1,500g for 10
min at 4°C, washed twice, and resuspended in PBS (4°C) to
the required concentration, stored at 40C, and used within 1 h;
there was no loss in colony-forming uinits (CFU) on storage
for at least 4 h. A 1% suspension of E. coli K+ adjusted to an
OD of 0.410 at 540 nm yielded 2.65 x 108 CFU/ml; 0.2% sus-
pensions of E. coli K- and E. coli 09:K9-:H12 adjusted to an
OD of 0.510 at 540 nm yielded 2.5 and 2.8 x 108 CFU/ml,
respectively.
Hutmtizan sera. Venous blood was clotted in siliconized
glass test tubes, stored for 1 h at room temperature and an
additional 1 h at 40C, and the normal serum (NS) separated
and stored at -700C. Complement activity was inactivated by
heating serum at 56°C for 30 min just before use. Absorbed
serum was prepared by successively incubating 30 ml of a
1:1 mixture of NS with PD three times with fresh batches of
1011 E. coli K+ and/or K- on a gyratory shaker at 40C for 1 h;
the bacteria had been grown to mid-log phase, washed in PD,
and pelleted by centrifugation. Absorbed serum was separated
from the bacteria by centrifugation, filtered (0.45 itm Milli-
pore filters; Millipore Corp., Bedford, Mass.), and stored
at - 700C.
Complement activity: classic pathway. Hemolytic ac-
tivity for antibody-coated sheep erythrocytes (RBC) in normal
and absorbed human serum was measured as described (29).
Normal human serum had 365 CH50 U/ml, serum absorbed
with E. coli K+ had 200 CH50 U/ml, serum absorbed with E.
coli K- had 200 CH56 U/ml, and serum absorbed with both
organisms had 250 CH50 U/ml.
Complement activity: alternative pathway. Hemolytic
activity of normal and absorbed sera for rabbit RBC was
measured by a modification of the method of Platts-Mills
and Ishizaka (30). A standard hemolysis curve (percentage
RBC on ordinate; OD units on abscissa) was generated by
incubating 200 ,lI of a suspension of rabbit RBC in concen-
trations ranging from 0 to 1% vol/vol in EGTA buffer (30)
with 400 ,ul of water for 5 min at 4°C, adding 2.5 ml of EGTA
buffer (4°C), centrifuging, and determining the OD of the
supernate at 412 nm on a Coleman 44 spectrophotometer.
Sera were assayed by incubating 200 Al of 1% rabbit RBC with
0-400 ,u of serum in EGTA buffer for 30 min at 370C,
stopping the reaction by adding 2.5 ml of EGTA buffer (4°C),
centrifuging, and determining the OD of the supernate. The
percentage ofhemolysis (y) was determined from the standard
hemolysis curve, and the 50% hemolytic titer was obtained
graphically on log-log paper by plotting on the x-axis the
amount of serum added, and on the y-axis the ratio y/100-y;
1,000 divided by the amount of serumil in microliters giving
50% hemolysis (x intercept) yielded CH50 alternative pathway
hemolytic activity (after Mayer) (29). Measured in this way,
normiial serum had 10.9 CH50 U/nml, serum] absorbed with E. coli
K+ had 9.7 CH50 U/mI11, serum] absorbed with E. coli K- ha(l
10.5 CH50 U/ml, and( serum absorbed with both organisms had
5.1 CH50 U/ml.
Preparation of IgM and IgG fractions of human serum.
Serum was dialized against 0.2 M NaCl, 0.1 M Tris-HCl, and
0.02% azide, pH 8.0, and IgM and IgG were separated on a
Sephadex G-200 columlln (Pharmnacia Finie Chemiiicals) as de-
scribed (29). Appropriate fractions were concentrated 100-fold
by pervaporation with a collo(lioni bag apparatus (Schleicher
and Schuell, Inc., Keenie, N. H.) and( teste(d for IgM and IgG by
double immunodiffusion using heavy chain-specific antisera.
Fractions free ofcross-contamination were combined and des-
ignated IgM or IgG fractions; these fractions were adjusted
to roughly the same volume as the serumil sample from which
they were obtained, dialyzed three times against 100-fold
volumes of PBS, filtered (0.45 ,tum Millipore filter), again
demiionistrated free of cross-contamninants b, dloul)le illimuino-
diffusion, and stored at -70'C. Examination of the IgM frac-
tion by immunoelectrophoresis (31) confirmed the absence of
IgG. The protein concentrations of the human IgM and IgG
fractions were 0.05 and 4.4 mg/ml, respectively (32).
Rabbit anti-E. coli K' IgM and lgG. New Zealand white
rabbits injected intravenously at 4-d intervals for 12 d with
increasing amounts of an E. coli K+ vaccine prepared as
described (33) yielded antiserum with a high titer of both
IgM and IgG antibody. IgM and IgG fractions were separated
by Sephadex G-200 chromatography, demonstrated free of
cross-contamination, and stored as described above for human
serum. The protein concentrations of the rabbit IgM and IgG
fractions were 0.8 and 6.1 mg/ml, respectively. 1 ml of a 1%
suispension of E. coli K+ in PBS was aggluitniiated by 25 ,ul
of IgM or 75 ,l of IgG.
Protein A absorption of rabbit IgM. The rabbit IgM frac-
tion was absorbed with protein A to assure complete removal
of IgG by diluting 350 ,ul of the IgM fraction 1:9 with PBS and
absorbing it twice at 4°C for 1 h with 0.1 -nl of gel containing
58 mg of dry protein A-Sepharose CL-4B (Pharmacia Fine
Chemicals). This amount of gel was in excess of that require(d
to remove all the IgG from 350 Al of a 1:9 dilution of the rabbit
IgG fraction.
Fluorescence microscopy of complement-coated bacteria.
3 x 106 mid-log phase bacteria were incubated for 15 min at
37°C with 600 ,tl of 25% normal or absorbed serum in PBS,
washed twice with PBS, incubated for 10 min at 37°C with a
mixture containing 20 ,ul of rhodamine-conjugated goat anti-
human C3 IgG and 80 ,ul PBS, washed again, resuspended
in 100 ul of PBS, and examined with a Zeiss Fluorescent
Photomicroscope III (Carl Zeiss, Inc., New York). IgM- and
IgG-mediated complement fixation to the surface of the E. coli
K+ was determined similarly, except in the initial step 1.5
x 106 bacteria were incubated with 0-60 ,ud of human IgM
or IgG fraction in a total volume of 300 ,ul of 10% absorbed
serum.
Attachment of bacteria to phagocytes with Con A. E. coli
were attached to mouse macrophages with Con A by washing
the macrophages three times with PBS (4°C), incubating them
with 125 ,ug Con A/ml PBS for 30 min at 4°C, again washing
them three times with PBS (4°C), and incubating them for 45
min at4°C with 1 ml ofa 2% suspension ofencapsulated E. coli
09:K29:H- (E. coli K+) or a 1% suspension of unencapsulated
E. coli 09:K9-:H12 for 45 min at 4°C. E. coli were attached to
PMN with Con A by incubating a 1% suspension of E. coli
K+ or E. coli 09:K9-:H12 with subagglutinating amounts of
Con A (250 ,tg/ml PBS for E. coli K+ and 8 ,ug/ml for E. coli
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09:K9-H 12) for 30 min at 4°C, washing and resuspending them
in PBS (4°C), and incubating 1 ml of a 2% suspension ofE. coli
K+ ora 1% suspension of E. coli 09:K9-H12 with PMN mono-
layer cultures for 10 min at 37°C; PMN monolayers were pre-
pared as described in Methods for PMN phagocytosis assay
I and washed three times in PBS. At the end of the incubations,
the monolayers were washed with PBS to remove unbound
bacteria.
PMN killing assay. In all killing assays, reactants (total
volume 900 ,l) were added to plastic tubes in an ice water
bath; the tubes were then gassed with 5% C02-95% air so that
the pH was 7.4 as judged by the color of the phenol red in-
dicator dye, capped, sealed with Parafilm (American Can Co.,
Greenwich, Conn.), and incubated at 37°C on a gyratory
shaker at 240 rpm. In most experiments, human imnmuno-
globulin, autologous serum (normal, absorbed, or heat
inactivated), 5 x 106 PMN in 500 u1 HBSS, or the various
controls for these reactants, and 0.5 or 1 x 106 bacteria
in 100 ,u of PBS, were added in that order. In experiments
involving rabbit immunoglobulin, the immunoglobulin and
bacteria were added first and incubated at room temperature
for 10 min before other reactants were added as above. A
separate tube was used for each time point; thus tubes were
not opened until the end of the incubation. At that time, the
tubes were placed in an ice water bath to stop the reaction,
and the contents were sonicated under sterile conditions with
an amount of energy sufficient to lyse leukocytes completely
(as measured by phase-contrast microscopy) but not to reduce
bacterial CFU. To determine the number ofCFU, the contents
of each tube were serially diluted in PBS (4°C), spread onto
100 x 15-mm TSB agar plates using a glass spreader and a
rotating wheel (Rota-Plate, Fisher Scientific Co., Pittsburgh,
Pa.), incubated overnight at 37°C, and colonies counted man-
ually with a colony counter (New Brunswick Scientific Co.,
Inc., Edison. N. J.).
Monocyte killing assay. The assay was identical to the
above except that mononuclear cells rather than PMN were
added to the reaction mixture. On the basis of the differential
cell count, 2.5 x 106 monocytes were incubated with 5 x 105
E. coli K+ (monocyte:bacteria ratio of 5: 1).
PMN phagocytosis assay 1: PMN in monolayer. PMN
(1.25 x 105 in 75 /l HBSS) were allowed to attach to 13-mm
Diam glass coverslips in 16-mm Diam culture wells (Costar
Data Packaging, Cambridge, Mass.) for 15 min at 37°C under
5% C02-95% air atmosphere after which the various serum
preparations and 6.25 x 105 bacteria in a total volumiie of 300
gl were added to each well. The wells were gassed with a 5%
CO2-95% air mixture, the entire 24-well unit sealed with
Parafilm, and the unit incubated for 20 min at 37°C on a gyra-
tory shaker at 140 rpm. Each coverslip was then washed with
ice-cold PBS, fixed in 2.5% glutaraldehyde in PD, mounted
on a glass slide, and examined by phase-contrast microscopy;
over 100 PMN in random fields were examined, and the per-
centage of PMN with vacuoles containing bacteria deter-
mined.
PMN phagocytosis assay II: PMN in suspension. This
assay, which allowed accurate counts of ingested bacteria,
was set up exactly as the PMN killing assay involving rabbit
immunoglobulin except that a total of 107 E. coli K+ were in-
cubated with 2.5 x 106 PMN (bacteria:PMN ratio of 4:1) for
30 min; afterward, 100-,ul samples from each tube were cyto-
centrifuged onto glass slides. The cells were fixed and stained
with Diff-Quik Fixative and Solutions (Harleco, American
Hospital Supply Corp., Gibbstown, N. J.) and the percentage
of PMN with cell-associated bacteria and the number of bac-
teria per ingesting PMN determined microscopically. As
94% of PMN with cell-associated bacteria had at least one
clearly intracellular bacterium by the criteria that the bac-
terium was in a vacuole and/or partially digested and at least
79% of all cell-associated bacteria were clearly intracellular
by these criteria, all cell-associated bacteria are tabulated as
phagocytosed bacteria (see Results).
Monocyte phagocytosis assay. This assay was identical to
PMN phagocytosis assay II except that mononuclear cells
rather than PMN were added to the reaction mixture. On the
basis of the differential cell count, 106 monocytes were in-
cubated with 107E. coli K+ (bacteria:monocyte ratio of 10:1).
RESULTS
The influence of the capsule on ingestion of E. coli
attached to phagocytes with Con A and the role of
antibody and complement in ingestion ofencapsulated
and unencapsulated strains. To examine the in-
fluence of the capsule on the attachment and ingestion
stages of phagocytosis, we first asked whether ingestion
automatically follows attachment of E. coli to the sur-
face of phagocytic leukocytes or whether antibody and
complement are additionally required. At the same
time, we asked whether the presence of a capsule in-
fluences the fate of bacteria once they are attached.
To answer these questions, we required a method of
attaching E. coli to phagocytes without antibody and
complement. For this purpose, we used Con A, as de-
scribed in NMethods; over 98% of macrophages and
PMN had adherent bacteria, usually 10-20 bacteria/
PMN and 20-50/macrophage.
Encapsulated E. coli 09:K29:H- (E. coli K+) bound to
the surfaces of resident or thioglycollate-elicited mouse
peritoneal macrophages or human PMN with Con A
were not ingested on incubation of the bacteria-
leukocyte complexes in PBS or minimal essential me-
dium without glucose at 37°C for 1-3 h; glucose-free
medium was used because glucose is a competitive
inhibitor of Con A and promotes the release of bacteria
from the leukocyte surface. In fact, these bacteria multi-
plied on the sturface of the phagocytes. After 1-3 h
incubation, these E. coli were eluted from the phago-
cyte surface with 100mM aMM, a competitive inhibitor
of Con A (Fig. 1). In contrast, unencapsulated E. coli
09:K9-:H12 bound to the phagocytes with Con A were
ingested by >95% of the phagocytes on incubation in
PBS or minimal essential mediuim without glucose at
37°C for 1-3 h.
Other experiments confirmed that Con A does not
promote phagoeytosis of encapsulated E. coli. We ob-
served no ingestion when we treated E. coli-macro-
phage complexes (formed as described in Methods or
by coating the bacteria w\ith a subagglutinating dose of
Con A anld incub)ating themii wvith macrophages for 30
min at 4°C) wNith excess Coni A (125-250 ,.g/mnl) before
(45 min at 4°C) or during the 37°C incubation.
Encapsulated E. coli were ingested by >95% of
macrophages when 5% rabbit anti-E. coli K+ antiserum
or 5% goat anti-Con A antiserum was added to the
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FIGURE 1 PMN do not phagocytose encapsulated E. coli attached to the PMN surface with Con A.
E. coli K+ PMN complexes were incubated in PBS at 37°C for 1 h and examined by phase-contrast
microscopy before (A) and after (B) treatment with 100mM a-methyl-D-mannopyranoside. x 1,350.
media containing the complexes of resident or thio-
glycollate-elicited macrophages and Con A-coated E.
coli. However, 10-20% fresh mouse serum from non-
immune mice (a source of complement but not anti-
body) did not induce ingestion of these bacteria.
In control experiments without Con A, encapsulated
E. coli were not attached or ingested when incubated
with resident or thioglycollate-elicited macrophages at
37°C for 1 h in the presence or absence of 10% fresh
mouse serum. In contrast, unencapsulated E. coli 09:
K9-:H12 were attached and ingested in medium con-
taining fresh mouse serum, but not in serum-free
medium.
We derived three conclusions from these experi-
ments: (a) attachment of unencapsulated E. coli to the
surface of a phagocyte is sufficient to induce ingestion
of the unencapsulated bacteria; (b) attachment of en-
capsulated E. coli is insufficient to induce ingestion of
these bacteria. Serum ligands, in this instance anti-
bodies to bacterial surface antigens or to Con A on the
bacterial surface, are required to promote phagocytosis;
(c) in the absence of antibody, fresh mouse serum (a
source of complement) promotes attachment and sub-
sequently ingestion of unencapsulated E. coli, but is
unable to promote either attachment or ingestion of en-
capsulated E. coli.
The experiments with fresh mouse serum strongly
suggested that unencapsulated but not encapsulated
E. coli fix complement in the absence of antibody and
consequently are phagocytosed by phagocytes in the
absence ofantibody. To test this hypothesis, we studied
phagocytosis and killing of an encapsulated E. coli
(E. coli K+) and an unencapsulated mutant (E. coli
K-) of the same strain by human PMN and monocytes.
Killing of encapsulated and unencapsulated E. coli
by human PMN in the presence of normal human
serum. To determine the optimal ratio of PMN:
bacteria for in vitro killing, we incubated E. coli K+
and K- with 5 x 106 PMN in 10% autologous normal
human serum at 37°C for 1 h so that the ratio of PMN:
bacteria ranged from 0.3:1 to 37.5:1. Killing occurred
only in the presence ofPMN. A 2-log reduction in CFU
was obtained independent of the ratio of PMN:bacteria
and of the status of encapsulation.
To study the kinetics of killing, we incubated 5 x 105
E. coli K+ or K- with 5 x 106 PMN (PMN:bacteria ratio
of 10:1) in 10% normal serum at 37°C for periods
ranging from 0 to 120 min. Bacteria were killed only in
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the presence of both PMN and serum (Fig. 2). Maximal
killing was achieved by 60 min of incubation, and most
or all of this occurred in the first 30 min. The rate of
killing of encapsulated E. coli was similar to that of
inencapsulated E. coli.
To study the effect of the concentration of normal
serum on PMN killing, we incubated 5 x 105 E. coli
K+ or K- with 5 x 106 PMN at 37°C for 1 h in medium
containing 0-20% normal serum. With low serum con-
centrations (0.1 and 1%), significant (1 log) killing of
the E. coli K- straini occurred but there wvas no killing of
the E. coli K+ straini. \Vith higher concentrations of
serum (5, 10, and 20%), significant killing (2-2.5 logs)
of both E. coli K+ and K- strains occurred. Maximal
killing ofboth strains occurred with 10 and 20% serum.
Roles of antibody and complement in the killing
of etLcapsulatecl (10(1 uneflcaIpsullated E. coli by PMIN.
To examine the role of complement in the absence
of antibody in the killing of E. coli by PMN, we ab-
sorbed normal human serum with E. coli K+ and K-. To
grossly compensate for the 31% reduction in classic
and 52% reduction in alternative complement pathway
activities that occurred with absorption of the serum,
we increased the concentration ofabsorbed serum from
10 to 15% in some samples. Heat-inactivated normal
human serum served as a source of antibody. Several
lines of evidence, described in later sections of this
paper, confirmed that the human serum used in these











FIGURE 2 Rate of killinig of E. coli K+ anid K- by P.MN. P.MN
(5 x 106) were incubated with 5 x 105 E. coli K+ (left) or E. coli
K- (right) in 10% normal serum (NS) at 370C for periods
ranging from 0 to 120 min; CFU of E. coli were determined














FIGURE 3 PMN killing of E. coli K+ and K- in the presence
of absorbed (Abs S), heat-inactivated (HI), or normal serum
(NS). PMN (5 x 106) were incubated with 106 E. coli K+ (left)
or E. coli K- (right) at 37°C for 1 h in the presenice of the serumii
preparations indicated. CFU of E. coli were determined ini-
tially and at the end of the incubation.
PMN were unable to kill E. coli K+ or K- in the
presence of heat-inactivated serum (Fig. 3). In the
presence of absorbed serum (as a complement source),
PMN readily killed E. coli K- (2 logs) but were unable
to kill E. coli K+. However, PMN killed E. coli K+ in the
presence of normal serum. We conducted these experi-
ments with a PMN:bacteria ratio of 5:1. WVe obtained
similar results with a PMN:bacteria ratio of 50:1
(5 x 106 PMN: 105 bacteria). Thus, the inability of PMN
to kill E. coli K+ in the presence of absorbed serum
was not a consequence of an inadequate ratio of PMN:
bacteria.
We derived two important conclusions from the
results of these experiments: (a) complement is re-
quired for the efficient killing of E. coli K+ and K- by
PMN; (b) in the presence of complement, antibody is
required to promote killing of encapsulated but not
unencapsulated E. coli by PMN.
In other experiments, we determined that adequate
levels ofboth antibody and complement are required to
achieve maximal killing ofE. coli K+. With the antibody
level held constant, PMN did not kill E. coli K+ sig-
nificantly with 0.1-1% absorbed serum but killed them
maximally (3 logs) with 5-10% absorbed serum (Fig.
4A). Conversely, with the complement level held con-
stant, PMN did not kill E. coli K+ with 0-0.1% heat-
inactivated serum, but killed them significantly (1 log)
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FIGURE 4 Concentration of heat-inactivated normal serum
(antibody source) and ofabsorbed serum (complement source)
required forPMN killing ofencapsulated E. coli. PMN (5 x 106)
were incubated with 5 x 105 E. coli K+ at 37°C for 1 h with a
constant amount ofheat-inactivated normal serum (5% HI NS)
and varying amounts of absorbed serum (Abs S) (A) or a
constant amount of absorbed serum (5% Abs S) and varying
amounts of heat-inactivated normal serum (B); CFU were de-
termined initially and at the end of the incubation.
with 1% and maximally (3 logs) with 5% heat-inacti-
vated serum (Fig. 4B).
Control experiments showed that in the absence of
PMN neither E. coli K+ nor K- were killed, even when
a 50% concentration of normal serum was used. Thus
it seemed likely that the differences in serum require-
ments for PMN killing of E. coli K+ and K- reflected
differences in requirements for phagocytosis.
Roles ofantibody and complement in the phagocyto-
sis of encapsulated and unencapsulated E. coli by
PMN. In our phagocytosis studies, we increased the
ratio of bacteria:PMN to 5:1 to facilitate counting and
improve the accuracy of the assay.
Without complement (no serum or heat-inactivated
serum), PMN did not ingest either E. coli K+ or
(Table I). With complement and antibody (normal
serum), PMN ingested both E. coli K+ and K-. With
complement alone (absorbed serum at concentrations
of 10 or 15%), PMN ingested E. coli K- as avidly as
TABLE I
PMN Phagocytosis of E. coli K + and K - in the Presence
ofAbsorbed, Heat-inactivated, or Normal Serum
Percentage PMN
ingesting
Serum preparation E. coli K+ E. coli K-
None 0 0
Normal serum, 10% 83 66
Heat-inactivated normal serum, 10% 0 4
Absorbed serum, 10% 0 65
Heat-inactivated absorbed serum, 10% 0 1
Absorbed serum, 15% 0 67
PMN (1.25 x 105) in a monolayer on coverslips were incu-
bated with 6.25 x 105 E. coli K+ or K- for 20 min at 37°C in
the presence of the serum preparation indicated. At the end of
the incubation, the coverslips were washed, fixed, examined
by phase-contrast microscopy, and the percentage of PMN
with intracellular bacteria determined.
with antibody and complement, butPMN did not ingest
E. coli K+.
Thus, the requirements for PMN phagocytosis of
E. coli K+ and K- precisely mirrored the requirements
for PMN killing of these bacteria: antibody and com-
plement were required for phagocytosis of encapsu-
lated E. coli, whereas complement alone sufficed for
phagocytosis of unencapsulated E. coli. The simplest
explanation for the differences in requirements be-
tween the two organisms was that antibody was re-
quired for fixation of complement onto the encapsu-
lated but not the unencapsulated E. coli.
Antibody is required to fix complement to encapsu-
lated but not to unencapsulated E. coli. To establish
the requirements for complement binding to E. coli
K+ or K-, we incubated these bacteria with absorbed
serum (complement) or whole normal serum (comple-
ment and antibody) and then with rhodamine-con-
jugated goat antihuman C3 IgG and examined them by
fluoresence microscopy. After incubation in normal
serum (antibody and complement), both E. coli K+
and K- bound complement as evidenced by very bright
fluorescence of the bacteria (Fig. 5). With complement
alone, the encapsulated bacteria exhibited no fluores-
cence but the unencapsulated bacteria fluoresced
brikhtly. Neither type of bacteria exhibited fluores-
cence when incubated with heat-inactivated normal or
heat-inactivated absorbed serum.
Thus, antibody is required for binding complement
to encapsulated but not to unencapsulated E. coli. The
serum requirements for complement binding are
identical to those for phagocytosis and killing by PMN.
In other words, unless the bacteria are coated with
complement, PMN can neither phagocytose nor kill
them efficiently.
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FIGURE 5 Complement fixation to encapsulated E. coli in the
presence of antibody and complement. E. coli K+ were in-
cubated in normal serum, washed, incubated in rhodamine-
conjugated goat antihuman C3 IgG, and examined by fluores-
cence microscopy. x 1,200.
Role of the coiiiplemnent and imnutnolobulin
receptors in killing (iand phaocijto.sis of enicapstulated
E. coli byl hum) an PAIN. Having determined that
phagocytosis and killing of the encapsulated E. coli
were dependent upon both antibody and complement,
we now sought to deterniine the roles of the C3 and Fe
receptors of human PMN in this process. To study C3
receptor function independent of the Fc receptor, we
used IgM to fix complement to the bacterial surface.
Fc receptors ofhuman PMN do not bind IgM. To study
Fc receptor function independent of the C3 receptor,
we used IgG in the absence of complement. We ob-
tained human IgM and IgG free of detectable con-
tamination with each other as described in Methods.
By fluorescence microscopy, we confirmed that both
immunoglobulin preparations promoted the binding of
complement to E. coli K+ in a dose-dependent fashion,
i.e., fluorescence appeared and then increased as the
amount of immunoglobulin added was increased from
0 to 60 ,1 (see Methods).
Both the IgM and IgG fractions efficiently promoted
killing of E. coli K+ by PMN (Fig. 6). When added
together, the two immunoglobulins acted synergisti-
cally; when 9 ,ul ofIgG was added to 90 gl ofIgM, killing
was enhanced by an additional log over that seen with
90 ,ul of IgM alone. Bacterial killing was similarly
augmented when 9 ,ul ofIgM was added to 90 gl of IgG
in the same assay. The amount ofeach immunoglobulin
preparation required for significant bacterial killing
(90 and 180 ,AI) was roughly equivalent to that present
in 10 (90 ,ul) and 20% (180 ul) normal serum, respec-
tively. Control experiments showed that in the absence
of complement neither human immunoglobulin frac-
tion promoted killing of E. coli K+ by PMN.
The capacity of IgM and complement to promote
killing of E. coli K+ by PMN indicates that these
bacteria are phagocytosed via PMN complement re-
ceptors. This finding was surprising in view of the re-
port of Ehlenberger and Nussenzweig (34) that the C3
receptor of PMN mediates attachment but not phago-
cytosis of complement-coated sheep RBC, and that Fc
receptor function is required for efficient phagocytosis
of sheep RBC. To confirm our results, we repeated the
killing experiments with high titer rabbit anti-E. coli
K+ IgM and IgG. By double immunodiffusion against
goat anti-rabbit IgG, the undiluted rabbit IgM fraction
gave no precipitin line, whereas a 1:99 dilution of the
IgG fraction yielded a clear precipitin line. To elimi-
nate the possibility that trace amounts of IgG might be
contaminating the IgM preparation, we absorbed the
rabbit IgM fraction twice with an amount of protein
A-Sepharose in excess of that sufficient to remove all
opsonic activity from an equal volume of the IgG frac-
tion of this antiserum, as measured by the bacterial
killing assay, and all traces of IgG from the same IgG
fraction as measured by double immunodiffusion;
protein A complexes with >97% of rabbit IgG (35).
In the presence of absorbed serum as a complement
source and either rabbit IgG or protein A-absorbed
rabbit IgM, PMN killed E. coli K+ (Table II). With
complement and both IgM and IgG, PMN killed sig-
nificantly more E. coli K+ than with either immuno-
globulin alone. Without complement, PMN killed E.
coli K+ with IgG but not IgM; under these,pircum-
stances, killing occurred only at the higher dose of IgG
employed (0.04 agglutinating dose). These results con-
firmed that PMN kill E. coli K+ in the presence of anti-
E. coli K+ IgM and complement; IgG is not required.
With IgG, PMN kill E. coli K+ more efficiently in the
presence of complement than in its absence.


























PMN +90 ml IgG+AbsS
PMN+NSPMN+180lB IgG+AbsS
Incubation time (h)
FIGURE 6 PMN killing of encapsulated E. coli in the pres-
ence of human IgM and IgG. PMN (5 x 106) were incubated
with 106 E. coli K+ in the presence of Abs S and varying
amounts of human IgM (left) or IgG (right) at 370C for 1 h;
CFU were determined initially and at the end of the incu-
bation.
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TABLE II
PMN Killing of Encapsulated E. coli in the Presence
of Rabbit 1gM and IgG
Log change in CFU after
incubation with PMN and/or Abs S
PMN
Antibody preparation PMN Abs S + Abs S
None 0.4 0
HI rabbit serum (0.20 AD)* 0.2 0.2 -2.4
HI rabbit serum (0.04 AD) -0.1 0.2 -1.9
IgM (0.04 AD) 0.5 -0.1 -1.3t
IgG (0.04 AD) -0.8 0.2 -2.5
IgM (0.008 AD) 0.7 0.1 -1.3
IgG (0.008 AD) 0.4 0.1 -1.4
IgM (0.008 AD) plus
IgG (0.008 AD) 0.2 0.1 -2.0
PMN (2.5 x 106) and/or Abs S (as a source of complement)
were incubated with 4 x 105 E. coli K+ in the presence of
no antibody, heat-inactivated rabbit serum (0.04 and 0.20 AD),
protein A absorbed IgM (0.04 and 0.008 AD), IgG (0.04 and
0.008 AD), or IgM plus IgG (0.008 AD of each) at 37°C for
1 h. CFU were determined initially and at the end of the
incubation.
* An agglutinating dose (AD) was the minimal concentration
of antibody required to agglutinate E. coli K+ under the
conditions described in Methods.
I A -1.3 log change in CFU was also observed in a control
sample containing IgM not absorbed with protein A.
immunoglobulin was a consequence of phagocytosis
of E. coli K+, we measured ingestion of these bacteria
by PMN using the PMN phagocytosis assay II de-
scribed in Methods. As expected, in the presence of
absorbed serum, we found an excellent correlation be-
tween the capacity of rabbit IgG or IgM to promote
phagocytosis (Table III) and their capacity to promote
killing (Table II) of E. coli K+ by PMN.
Phagocytosis and killing of E. coli K+ by human
blood monocytes. To determine the opsonic require-
ments for phagocytosis and killing of E. coli K+ by hu-
man blood monocytes, we performed experiments
similar to those described above for PMN. As shown in
Table IV and Fig. 7, the serum requirements for phago-
cytosis and killing of E. coli K+ by monocytes were
similar to those observed for PMN. Monocytes phago-
cytosed and killed E. coli K+ efficiently only in the
presence of complement and antibody (either IgM
or IgG).
In obtaining monocytes, we found by chance that if
the blood were dextran-sedimented before application
to Ficoll-sodium diatrizoate (instead of being applied
directly), the mononuclear fraction thus obtained was
heavily contamiiniiatedl with PMN and consisted on the
average of40% monocytes, 36% PMN, and 24% lymph-
ocytes. This allowed a comparison of the phagocytic
capabilities of PMN and monocytes obtained in com-
parable numbers under identical conditions. When we
reacted 4 x 106 E. coli K+ with a mixture containing
-106 monocytes and 106 PMN under the same con-
ditions as in Tables III and IV, we found that PMN
were strikingly superior to monocytes in phagocytic
capability. The phagocytic indices for PMN and mono-
cytes were 620 and 89, respectively, in the presence of
IgM and complement, and 370 and 31, respectively,
TABLE III
PMN Phagocytosis of E. coli K+ in the Presence of Rabbit IgM and IgG
Percentage of Nuimiber of
PMN ingesting E. coli per Phagocytic
Opsonin(s) added E. coli PMIN inigestinig index*
Normal serum (human) 96 5.6 538
Abs S (human) 2 1.0 2
IgM (0.04 AD)t 0 0
IgM (0.04 AD) plus Abs S 92 4.8 441
IgG (0.04 AD) 3 1.3 4
IgG (0.04 AD) plus Abs S 85 2.8 239
HI rabbit serum (0.04 AD) 21 3.3 70
HI rabbit serum (0.04 AD) plus Abs S 99 5.9 585
PMN (2.5 x 106) were incubated with 1 x 107 E. coli K+ for 30 min at 37°C in the presence
of normal human serum (10%) or in the presence of absorbed human serum (10%) and/or
0.04 AD of IgM, IgG, or the heat-inactivated rabbit antiserum from which the immuno-
globulins were fractionated. At the end of the incubation, the cells were cytocentrifuged
on to glass slides, fixed, stained, examined by bright field microscopy, and the number of
PMN ingesting bacteria and the number of such bacteria per ingesting PMN determined as
described in detail in Methods.
* Phagocytic index is the percentage of PMN with ingested E. coli K+ multiplied by the
average number of E. coli K+ ingested per PMN.
t See legend for Table II.
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TABLE IV
Monocyte Phagocytosis of E. coli K+ in the Presence of Rabbit IgM and IgG
Percentage of Number E. coli
monocytes per monocyte Phagocytic
Opsonin(s) added ingesting E. coli ingesting index
Normal serum (human) 83 4.5 374
Abs S (human) 1 1.0 1
IgM (0.04 AD)* 0 0 0
IgM (0.04 AD) plus Ab S 49 3.2 157
IgG (0.04 AD) 11 2.6 29
IgG (0.04 AD) plus Abs S 53 3.0 160
HI rabbit serum (0.04 AD) 21 2.2 46
HI rabbit serum (0.04 AD) plus Abs S 79 4.9 389
Monocytes (1 x 106) were incubated with 1 x 107 E. coli K+ under the same conditions
as for PMN in Table III, and phagocytosis
for PMN in Table III.
* See legend for Table II.
in the presence of IgG and complement; in these prep-
arations, nearly all the bacteria were in PMN. However,
with IgG or heat-inactivated antiserum alone, we found
that monocytes and PMN had comparably low phago-
cytic capacities (indices s 40). This suggested that the
complement receptor of the PMN is more efficient
than the complement receptor of the monocyte in pro-
moting phagocytosis of complement-coated encapsu-
lated bacteria, but that the Fc receptors of the two
phagocytes are comparably efficient.
DISCUSSION
The surfaces of most unencapsulated gram-negative
bacteria are rich in lipopolysaccharide. In the absence
of antibody, it is presumably the interaction of this
surface with complement components that activates the
complement pathway and leads to the deposition of
complement onto the bacterial surface; lipopolysac-
charide has been shown capable of fixing complement
without antibody (36). Our experiments indicate that
the E. coli capsule blocks complement fixation to the
bacterial surface, probably by masking surface com-
ponents, such as lipopolysaccharide, capable of acti-
vating the complement pathway. The capsule itself
does not promote complement binding; complement is
bound to the surface of encapsulated E. coli only when
specific IgM or IgG antibody is present. Once com-
plement is bound, encapsulated and unencapsulated
E. coli are equally phagocytosed and killed by PMN.
Unencaps-ulated E. coli, when attached to phagocytic
leukocytes by Con A, do not require either complement
or antibody for ingestion; however, under physiologic
conditions, i.e., in the absence of plant lectins, they
require complement. This suggests that under physio-
logic conditions, complement and complement re-
ceptor activity are required for attachment but not in-
gestion of unencapsulated E. coli. In contrast, encap-
was assayed in the same way as described
sulated E. coli, even when attached to the leukocyte
surface with Con A, require serum opsonins such as
antibody or complement for ingestion. It follows that
under physiologic conditions, complement and/or Fc
receptor activity are required for both the attachment
and the ingestion stages of phagocytosis of encapsu-
lated E. coli. Griffiin et al. (37) have come to a similar
conclusion in their studies of phagocytosis of IgG and
complement-coated RBC by mouse peritoneal macro-
phages.
Encapsulated E. coli coated with IgM and comple-
ment are phagocvtosed by PMIN and monocvtes; these
Abs IgG+AbsS












FIGURE 7 Mtonocyte killing of encapsulated E. coli in the
presence of rabbit IgM and IgG. Monocytes (2.5 x 106) were
incubated with 5 x 105 E. coli K+ in the presence of Abs S
and rabbit IgM or IgG at 37°C for 1 hr; CFU were determined
initially and at the end of the incubation. HI RS, heat-inac-
tivated rabbit serum.
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leukocytes lack receptors for IgM. This indicates that
the complement receptors of PMN and monocytes
mediate the ingestion of complement-coated encap-
sulated bacteria. In contrast, Ehlenberger and Nus-
senzweig have reported that the complement receptors
of PMN and monocytes do not promote the ingestion
of complement-coated sheep RBC (34). We cannot
explain these differences in the response of PMN and
monocytes to complement-coated sheep RBC and en-
capsulated E. coli.
The relative roles of complement and antibody in
promoting phagocytosis of bacteria coated with these
ligands are of more than academic interest. Our re-
sults indicate that a host lacking specific IgM or IgG
antibacterial antibody might be susceptible to infection
with encapsulated but not unencapsulated bacteria.
Early in the course of an infection, IgM may be the
only antibacterial antibody present. Inasmuch as PMN
and monocytes have no IgM receptors, complement
would be the only serum ligand available to promote
clearance of encapsulated bacteria.
Three points should be taken into account in studying
complement binding to bacteria. First, the state of en-
capsulation of the bacteria is an important determinant
of their capacity to bind complement. The amount of
capsular material present may vary with different cul-
ture conditions. Second, serum must be thoroughly
absorbed to remove natural and cross-reacting antibody
from "nonimmune" serum; otherwise, a requirement
for antibody for complement fixation may be missed.
Third, serum must be absorbed with both encapsulated
and unencapsulated bacteria to remove all antibacterial
antibody. Absorption with encapsulated blacteria alone
does not effectively remove antibody to subcapsular
surface antigens such as the somatic 0 antigen. In
studies whose details are not included here, we found
that serum absorbed with only E. coli K+ promoted
phagocytosis and killing of E. coli K.+ Serum absorbed
with both E. coli K+ and K- was inactive in the absence
of added antibody (Figs. 3, 4, 6, and 7; Tables I-IV).
These findings suggest that antibodies directed against
somatic antigens can react with encapsulated E. coli
and promote the binding of complement to their
surface. The reports of Kaijser et al. (15), and Kaijser
and Olling (14) that antibody to the somatic 0 antigen
of encapsulated E. coli protected animals against in-
fection with these bacteria are consistent with this
view. On the other hand, a large capsule may render
subcapsular surface antigens totally inaccessible to
antibody, thus preventing antibody to the 0 antigen
from mediating complemenit fixation; Howard and
Glynn (4) reported that anti-OK antibody but not ainti-O
antilbody enhanced the clearance of initravenously
injected encapsulated E. coli.
Complement consumption by bacteria may not be
synonymous with complement binding to the bacteria.
Bacteria release substances such as proteases and
endotoxin that cause complement consumption in the
fluid phase (38). Similarly, complement fixation to
isolated bacterial structures (e.g., cell walls, cell mem-
branes, peptidoglycan) may not be relevant to the in
vivo situation where anatomical barriers such as a
capsule may limit access of complement components
to these structures in the intact bacterium. For these
reasons, we studied complement binding to intact
bacteria directly by using rhodamine-conjugated anti-
human C3 IgG.
The fluorescent antibody assay for complement fixa-
tion described in this paper is a simple, rapid, sensitive,
reliable, and inexpensive technique for determining
whether antibody is required to fix the third component
of complement to the surface of any bacterium of in-
terest. To screen a particular bacterium with this assay,
one requires only appropriately absorbed serum. Be-
cause antibody is required for complement binding and
phagocytosis of encapsulated E. coli, determining
whether or not antibody is required to bind comple-
ment to other bacterial species may provide insight into
requirements for antibody in host defense against them.
On the basis of our findings, we postulate the fol-
lowing model for the interaction of bacteria (except
intracellular parasites) with the host humoral and
cellular defense systems. When unencapsulated gram-
negative bacteria encounter serum, their lipopoly-
saccharide-rich outer membrane promotes comple-
ment fixation to the bacterial surface. Consequently,
the bacteria are either lysed by late-acting complement
components or ingested and removed by phagocytic
leukocytes. When encapsulated gram-negative bacteria
encounter serum, complement is not fixed to the bac-
terial surface in the absence of specific antibacterial
antibody. Consequently, encapsulated bacteria are re-
sistant to complement lysis and phagocytosis. This may
account, at least in part, for the enhanced pathogenicity
ofencapsulated gram-negative bacteria. If specific anti-
body is available, complement is bound and the en-
capsulated bacteria are either lysed or phagocytosed.
This model may also apply to gram-positive bacteria.
The capsules of gram-positive organisms are also im-
portant determinants of virulence; in the case of pneu-
mococcus, the role of anticapsular antibodies in host
defense has been recognized for a half century. The
outer surface of the unencapsulated gram-positive
bacteria, a cell wall containing peptidoglycan, has been
shown to promote complement activation (39, 40) and
Wilkinson et al. (41) have provided evidence that the
capsule of Staph ilococctis aureus hinders phagocyto-
sis by masking the underlying peptidoglycan layer.
Thus, the principles derived from our studies of en-
capsulated and unencapsulated E. coli may be relevant
to encapsulated and unencapsulated gram-positive
bacteria as well.
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